Delivery Order SPE2DB20D3303-SPE2DB25FA4EK
- Not listed
- The Defense Logistics Agency awarded a $11,895.72 delivery order to AmerisourceBergen Drug Corp for INLYTA 5 mg tablets (60-count units) on August 19, 2025, with an ultimate completion date of September 10, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of INLYTA 5 mg tablets (60-count units) with a ceiling value of $11,895.72. This firm fixed price delivery order, with an ultimate completion date of September 8, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Inlyta 5 mg tablets (60-count units) valued at $23,791.44. This firm fixed-price delivery order, with an ultimate completion date of August 29, 2025, represents a competitive award with no set-aside designation. The contract is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of INLYTA 5 mg tablets (60-count units) with a ceiling value of $11,895.72. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was made through competitive procurement with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $11.9K to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Inlyta 5 mg tablets (60-count units). The contract is firm fixed price with an ultimate completion date of October 2, 2025, and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs across...
- The Defense Logistics Agency awarded a $23,847.20 delivery order to AmerisourceBergen Drug Corp for 180 tablets of INLYTA 1 mg, a pharmaceutical product used in cancer treatment. This firm fixed-price delivery order, issued on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $23,847.20 to supply 180 tablets of INLYTA 1 mg, a pharmaceutical product for cancer treatment. This non-competitive, firm fixed-price delivery order was awarded on June 5, 2025, with a completion date of June 27, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery...
- This delivery order, valued at $23,791.44 with an ultimate completion date of September 12, 2025, awards AmerisourceBergen Drug Corp the supply of INLYTA 5 mg tablets (60-count units) under a firm fixed-price arrangement. The award was made competitively with no set-aside designation by the Defense Logistics Agency (DLA), which procures medical supplies and pharmaceuticals for the Department of Defense and military healthcare systems. The place of performance is AmerisourceBergen's corporate...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $11.9K by the Defense Logistics Agency (DLA) on June 2, 2025, for the supply of INLYTA 5 mg tablets (60-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of June 24, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1.0B global...
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Inlyta 5 mg tablets (60-count units) with a ceiling value of $11,895.72. This non-set-aside contract, awarded on July 21, 2025, utilizes firm fixed pricing and is scheduled for completion by August 11, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA4EKDelivery Order
The Defense Logistics Agency awarded a $23.79K delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of INLYTA 5 MG tablets (60-count units). This firm fixed-price, non-competitive delivery order is scheduled for completion by October 16, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. As a child delivery order, this award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $1 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply a comprehensive range of medications and medical supplies to military healthcare systems worldwide. AmerisourceBergen Drug Corp, headquartered in Pennsylvania, serves as a major pharmaceutical distributor and critical federal vendor for military and veteran healthcare procurement. The company maintains an extensive portfolio of federal contract awards through the DLA Medical Supply Chain, supplying brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains. This award reflects the company's continued role as a key supplier within the Defense Health Agency's pharmaceutical support infrastructure, leveraging its position as one of multiple potential prime vendors under the DLA's Pharmaceutical Prime Vendor Global Program framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.8k | 9/24/25 |